Learning desk

MultiAgent EDU StackGather good sources. Teach what matters.
T5TauricResearch/TradingAgentsT5A Man Who Invented Modern AI (Before Everyone Else) – Jürgen Schmidhuber [video]T5GPT-4 finished training four years ago todayT5AI Settles a 25 Year-Old Problem We Left BehindT5What it was like working on LLMs and security at Meta (2022-2026)T5Ask HN: How do you go from writing code to deploying with agents?T5What Happened: OpenAI and HuggingFaceT5Apple says Mac users in China can connect to Alibaba's Qwen AI serviceT5Show HN: Try Benzi – A coding harness/agent beating Claude Code itself on SonnetT5The AI Apocalypse Is HereT3Auto mode is now the default in Claude Code for Pro, Max, and Team plansT5Show HN: Tura – Build agent that uses 80% less token and delivers better resultsT5TauricResearch/TradingAgentsT5A Man Who Invented Modern AI (Before Everyone Else) – Jürgen Schmidhuber [video]T5GPT-4 finished training four years ago todayT5AI Settles a 25 Year-Old Problem We Left BehindT5What it was like working on LLMs and security at Meta (2022-2026)T5Ask HN: How do you go from writing code to deploying with agents?T5What Happened: OpenAI and HuggingFaceT5Apple says Mac users in China can connect to Alibaba's Qwen AI serviceT5Show HN: Try Benzi – A coding harness/agent beating Claude Code itself on SonnetT5The AI Apocalypse Is HereT3Auto mode is now the default in Claude Code for Pro, Max, and Team plansT5Show HN: Tura – Build agent that uses 80% less token and delivers better results
← Dispatches

Cancer drug response and resistance: molecular mechanisms and combating strategies

Primary research

#1307

T1new
Topic
unassigned (set during synthesis)
First seen
2026-08-05 07:16:31
Last seen
2026-08-05 07:16:31

Source raw items (1)

  • Semantic Scholar2026-08-05 07:15:56
    Cancer drug response and resistance: molecular mechanisms and combating strategies

    Despite remarkable advances in cancer drug treatment, including chemotherapy, targeted therapy, and immunotherapy, therapeutic resistance remains a formidable clinical barrier, limiting durable responses and long-term survival. Drug resistance can be broadly categorized as intrinsic, where tumors fail to respond to initial treatment, or acquired, which emerges during or after therapy due to adaptive or evolutionary processes. A comprehensive understanding of the multifactorial and dynamic nature of resistance is essential for improving treatment efficacy. In this review, we systematically examine the molecular and cellular determinants of drug response and resistance across 22 cancer types, highlighting key resistance mechanisms such as compensatory pathway activation, phenotypic plasticity, immune evasion, enhanced DNA damage repair, and the survival of drug-tolerant persister cells. These mechanisms are further contextualized across major therapeutic modalities, supported by clinical trials. We also present emerging strategies to overcome resistance, including rational drug combinations, novel agents, microbiome modulation, adaptive and intermittent therapies and advanced drug delivery systems, each illustrated with representative clinical studies. Moreover, we discuss cutting-edge tools that are revolutionizing resistance research, including single-cell and spatial multiomic profiling, patient-derived tumor organoid and xenograft (PDO/PDX) models, and artificial intelligence (AI)-powered predictive analytics. By integrating insights across molecular, cellular, and clinical dimensions, this review offers a strategic framework for understanding and tackling cancer drug resistance, with important translational implications for the future of precision oncology.